Quantification of intratumoral heterogeneity of HER2 status in breast cancer.

被引：0
|
作者：
Horii, Rie
Matsuura, Masaaki
Nitta, Hiro
Ito, Yoshinori
Ohno, Shinji
Iwase, Takuji
Akiyama, Futoshi
机构：
[1] Japanese Fdn Canc Res, Inst Canc, Dept Pathol, Tokyo, Japan
[2] Japanese Fdn Canc Res, Inst Canc, Div Canc Genom, Tokyo, Japan
[3] Teikyo Univ, Grad Sch, Tokyo, Japan
[4] Ventana Med Syst Inc, Tucson, AZ USA
[5] Japanese Fdn Canc Res, Canc Inst Hosp, Breast Oncol Ctr, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.1036
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1036
引用
收藏
页数：5
相关论文
共 50 条
  • [21] HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
    Sasagu Kurozumi
    Mary Padilla
    Masafumi Kurosumi
    Hiroshi Matsumoto
    Kenichi Inoue
    Jun Horiguchi
    Izumi Takeyoshi
    Tetsunari Oyama
    Jim Ranger-Moore
    D. Craig Allred
    Eslie Dennis
    Hiroaki Nitta
    Breast Cancer Research and Treatment, 2016, 158 : 99 - 111
  • [22] HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
    Kurozumi, Sasagu
    Padilla, Mary
    Kurosumi, Masafumi
    Matsumoto, Hiroshi
    Inoue, Kenichi
    Horiguchi, Jun
    Takeyoshi, Izumi
    Oyama, Tetsunari
    Ranger-Moore, Jim
    Allred, D. Craig
    Dennis, Eslie
    Nitta, Hiroaki
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 158 (01) : 99 - 111
  • [23] Clinical significance of intratumoral HER2 heterogeneity in gastric cancer
    Lee, Hee Eun
    Park, Kyoung Un
    Yoo, Seol Bong
    Nam, Soo Kyung
    Park, Do Joong
    Kim, Hyung-Ho
    Lee, Hye Seung
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (06) : 1448 - 1457
  • [24] HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer
    Hou, Yanjun
    Nitta, Hiroaki
    Li, Zaibo
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2017, 147 (01) : 89 - 95
  • [25] Genotypic Intratumoral Heterogeneity in Breast Carcinoma With HER2/neu Amplification
    Brunelli, Matteo
    Manfrin, Erminia
    Martignoni, Guido
    Miller, Keith
    Remo, Andrea
    Reghellin, Daniela
    Bersani, Samantha
    Gobbo, Stefano
    Eccher, Albino
    Chilosi, Marco
    Bonetti, Franco
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2009, 131 (05) : 678 - 682
  • [26] Reply to 'Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance'
    Lee, Hee Jin
    Park, So Yeon
    MODERN PATHOLOGY, 2013, 26 (04) : 610 - 611
  • [27] Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer
    Cottu, P. H.
    Asselah, J.
    Lae, M.
    Pierga, J. -Y.
    Dieras, V.
    Mignot, L.
    Sigal-Zafrani, B.
    Vincent-Salomon, A.
    ANNALS OF ONCOLOGY, 2008, 19 (03) : 596 - 597
  • [28] Targeting HER2 heterogeneity in breast cancer
    Hamilton, Erika
    Shastry, Mythili
    Shiller, S. Michelle
    Ren, Rongqin
    CANCER TREATMENT REVIEWS, 2021, 100
  • [29] HER2 overexpressing metastatic breast cancer.
    Spigel D.R.
    Burstein H.J.
    Current Treatment Options in Oncology, 2002, 3 (2) : 163 - 174
  • [30] Disparities in HER2 testing in breast cancer.
    Paryani, Vijay
    Schroeder, Mary Chen
    Klepin, Heidi D.
    Melin, Susan Anitra
    Russell, Greg B.
    Winkfield, Karen Marie
    Thomas, Alexandra
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345